@Gassensmith @dasingleton @sciencegeist @Dereklowe @AOC I'm pleased to learn (mostly) that this iwas an incorrect factlet - the proportion of *prescriptions* is ~80/20 generics/non, but the proportion of *drug spending* is 20/80 generics/non. https://t.co/
RT @citizeness: Damn good chart from @Murray_Aitken, @Cutler_econ, and coauthors in today's HA https://t.co/Z6r9rXjXOC https://t.co/6cVtorS…
RT @Murray_Aitken: New @Health_Affairs is out now. What are your views on the future of #drug spending? >> https://t.co/gycUyLatVc https://…
RT @Murray_Aitken: New @Health_Affairs is out now. What are your views on the future of #drug spending? >> https://t.co/gycUyLatVc https://…
New @Health_Affairs is out now. What are your views on the future of #drug spending? >> https://t.co/gycUyLatVc https://t.co/lcoAf65au4
RT @Health_Affairs: Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.…
RT @Health_Affairs: Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.…
RT @Health_Affairs: Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.…
Enjoyed this piece from @Murray_Aitken et al in @Health_Affairs on #EconomicGrowth trends in #pharma https://t.co/1vG82rHyJW #health
RT @Health_Affairs: Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.…
RT @Health_Affairs: Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.…
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
RT @Health_Affairs: Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.…
Has The Era Of Slow Growth For Prescription Drug Spending Ended? @NIH @Murray_Aitken https://t.co/0EHWZPyxev https://t.co/NlDrKRqN3i
RT @jonathanrockoff: And here's a link to the @Health_Affairs article, which explains the complicated factors driving higher drug spend: ht…
RT @EvidenceSoup: The outlook for #pharma spending is uncertain, but there's reason to expect growth. New in @Health_Affairs - https://t.c…
And here's a link to the @Health_Affairs article, which explains the complicated factors driving higher drug spend: https://t.co/0M49I8ll3d
Great health affairs article on phrma spending trends, estimates of rebates especially innovative/helpful. https://t.co/sTI9ndeTk2
RT @Murray_Aitken: Has the era of slow growth for #prescription #drug spending ended? Find our take in a new @Health_Affairs issue >> htt…
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
RT @citizeness: Damn good chart from @Murray_Aitken, @Cutler_econ, and coauthors in today's HA https://t.co/Z6r9rXjXOC https://t.co/6cVtorS…
RT @onceuponA: New Health Affairs paper: come for the policy analysis, stay for the wordplay. https://t.co/3NYQhA5SdQ https://t.co/MwnlzvtN…
RT @Murray_Aitken: Has the era of slow growth for #prescription #drug spending ended? Find our take in a new @Health_Affairs issue >> htt…
Damn good chart from @Murray_Aitken, @Cutler_econ, and coauthors in today's HA https://t.co/Z6r9rXjXOC https://t.co/6cVtorSeBf
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
RT @EvidenceSoup: The outlook for #pharma spending is uncertain, but there's reason to expect growth. New in @Health_Affairs - https://t.c…
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
How to Slow Growth For Prescription Drug Spending Ended? https://t.co/ZC2v65Cqlc
RT @EvidenceSoup: The outlook for #pharma spending is uncertain, but there's reason to expect growth. New in @Health_Affairs - https://t.c…
RT @Murray_Aitken: Has the era of slow growth for #prescription #drug spending ended? Find our take in a new @Health_Affairs issue >> htt…
RT @Murray_Aitken: New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc http…
New @Health_Affairs study examines how discounts & rebates affect #prescription #drug spend https://t.co/gycUyLatVc https://t.co/EYJGjHSdUm
New Health Affairs paper: come for the policy analysis, stay for the wordplay. https://t.co/3NYQhA5SdQ https://t.co/MwnlzvtNan
RT @Murray_Aitken: Has the era of slow growth for #prescription #drug spending ended? Find our take in a new @Health_Affairs issue >> htt…
Has the era of slow growth for #prescription #drug spending ended? Find our take in a new @Health_Affairs issue >> https://t.co/gycUyLatVc
Has the era of slow growth for #prescription #drug spending ended? Find our take in a new @Health_Affairs issue >> https://t.co/gycUyLatVc
The outlook for #pharma spending is uncertain, but there's reason to expect growth. New in @Health_Affairs - https://t.co/pEQb0FeXIz
#HealthEconJA Has The Era Of Slow Growth For Prescription Drug Spending Ended? [Pharmaceutical Spending & Value] https://t.co/j1iFoFYTSA